We are live on
!
Find out more
Vanguard Capital Management Portfolio holdings
AUM
$4.68T
This Fund
S&P 500
This Quarter
Est. Return
-1.1%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.04T
AUM Growth
–
Cap. Flow
+$4.22T
Cap. Flow
% of AUM
104.32%
Top 10 Holdings %
Top 10 Hldgs %
32.57%
Holding
4,062
New
4,062
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$282B |
| 2 |
Apple
AAPL
|
+$248B |
| 3 |
Microsoft
MSFT
|
+$202B |
| 4 |
Amazon
AMZN
|
+$139B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$119B |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.5% |
| 2 | Financials | 12.85% |
| 3 | Healthcare | 9.93% |
| 4 | Consumer Discretionary | 9.89% |
| 5 | Communication Services | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3926
Inno Holdings
INHD
$36.3M
| $44.9K | ﹤0.01% |
+2,465
| New | +$58.1K |
|
3927
Reborn Coffee
REBN
$11M
| $44.7K | ﹤0.01% |
+22,709
| New | +$40.9K |
|
3928
Cosmos Holdings
COSM
$12.7M
| $44.4K | ﹤0.01% |
+140,007
| New | +$58.7K |
|
3929
Mangoceuticals
MGRX
$9.08M
| $44.3K | ﹤0.01% |
+123,041
| New | +$58.9K |
|
3930
Heart Test Laboratories
HSCS
$8.62M
| $44.2K | ﹤0.01% |
+17,968
| New | +$52.3K |
|
3931
Nexalin Technology
NXL
$7.48M
| $44K | ﹤0.01% |
+126,536
| New | +$65.9K |
|
3932
Pulmatrix
PULM
$5.62M
| $43.3K | ﹤0.01% |
+33,594
| New | +$79.7K |
|
|
MAMO
3933
Massimo Group
MAMO
$44.1M
| $42.4K | ﹤0.01% |
+42,600
| New | +$80.7K |
|
3934
Biofrontera
BFRI
$17.3M
| $42.3K | ﹤0.01% |
+52,254
| New | +$45K |
|
3935
Creative Medical Technology
CELZ
$7.25M
| $41.9K | ﹤0.01% |
+20,350
| New | +$39.8K |
|
3936
Hydrofarm Holdings
HYFM
$5.96M
| $40.5K | ﹤0.01% |
+39,683
| New | +$56K |
|
3937
Alaunos Therapeutics
TCRT
$4.71M
| $40.2K | ﹤0.01% |
+14,063
| New | +$42.1K |
|
3938
Socket Mobile
SCKT
$7.58M
| $40.1K | ﹤0.01% |
+46,130
| New | +$47.5K |
|
3939
Sonoma Pharmaceuticals
SNOA
$6.22M
| $40K | ﹤0.01% |
+18,787
| New | +$54.9K |
|
3940
Pasithea Therapeutics
KTTA
$16.1M
| $39.9K | ﹤0.01% |
+53,815
| New | +$45K |
|
|
FOXX
3941
Foxx Development Holdings
FOXX
$18.1M
| $39.6K | ﹤0.01% |
+8,313
| New | +$37.2K |
|
|
LNAI
3942
Lunai Bioworks
LNAI
$10.1M
| $39.4K | ﹤0.01% |
+12,062
| New | +$59.9K |
|
3943
Cardio Diagnostics
CDIO
$6.04M
| $39.3K | ﹤0.01% |
+20,155
| New | +$52.7K |
|
3944
Kiora Pharmaceuticals
KPRX
$11.3M
| $38.3K | ﹤0.01% |
+19,861
| New | +$41.9K |
|
|
SKYQ
3945
Sky Quarry Inc
SKYQ
$13.1M
| $38K | ﹤0.01% |
+14,796
| New | +$44.5K |
|
3946
cbdMD
YCBD
$5.2M
| $37.9K | ﹤0.01% |
+51,053
| New | +$43.6K |
|
|
RDIB
3947
Reading International Class B
RDIB
$209M
| $37.8K | ﹤0.01% |
+4,198
| New | +$48.1K |
|
3948
Theriva Biologics
TOVX
$10.9M
| $37.7K | ﹤0.01% |
+192,404
| New | +$37.9K |
|
|
RTB
3949
RTB Digital
RTB
$237M
| $37K | ﹤0.01% |
+7,351
| New | +$41.6K |
|
|
GRDX
3950
GridAI Technologies Corp
GRDX
$28M
| $37K | ﹤0.01% |
+18,293
| New | +$53.7K |
|
Similar funds
Vanguard Capital Management's Q1 2026 Portfolio in Review
Q1 2026 is the first quarter with a 13F filing on record for Vanguard Capital Management, which disclosed 4,062 positions worth $4.04T. Its ten largest holdings account for 33% of the portfolio.
Its largest position is NVIDIA: 1,538,550,382 shares worth $268B.
By sector, the portfolio is most concentrated in Technology at 31% of assets, followed by Financials and Healthcare.
- Vanguard Capital Management's largest Q1 2026 buy was NVIDIA: 1,538,550,382 shares worth $268B.
- Vanguard Capital Management's ten largest holdings make up 33% of its $4.04T portfolio in Q1 2026.
- Vanguard Capital Management disclosed 4,062 positions in Q1 2026, its first 13F filing on record.
Based on Vanguard Capital Management's 13F filing for Q1 2026, filed 8 May 2026.